Scarica l'app Stockscreener
14.54
1.89%
0.27
Pre-mercato:
13.88
-0.66
-4.54%
Precedente Chiudi:
$14.27
Aprire:
$14.25
Volume 24 ore:
986.76K
Relative Volume:
0.74
Capitalizzazione di mercato:
$1.87B
Reddito:
-
Utile/perdita netta:
$-42.76M
Rapporto P/E:
-45.32
EPS:
-0.3208
Flusso di cassa netto:
$-42.09M
1 W Prestazione:
+9.32%
1M Prestazione:
+30.29%
6M Prestazione:
+36.78%
1 anno Prestazione:
+138.36%
Intervallo 1D:
$14.02
$14.75
Intervallo di 1 settimana:
$12.76
$14.75
Portata 52W:
$5.3801
$14.75
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.54 | 1.83B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics prices $150M stock offering at $13 per share - Investing.com
Trevi Therapeutics, Inc. Prices Underwritten Public Offering of 11.6 Million Shares at $13.00 Each - Quiver Quantitative
Trevi sells 11.6M shares at $13, aiming to raise about $150M - Stock Titan
Trevi Therapeutics announces pricing of $150 million underwritten offering of common stock - marketscreener.com
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - Yahoo! Finance Canada
Trevi Therapeutics launches $150M public stock offering - MSN
Trevi Therapeutics launches $150M public stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics announces proposed public offering of common stock - marketscreener.com
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Trevi Therapeutics stock tumbles on public offering plan - Investing.com
Trevi Therapeutics stock tumbles on public offering plan By Investing.com - Investing.com India
Trevi Therapeutics (NASDAQ: TRVI) seeks $150M in stock offering; option $22.5M - Stock Titan
Trevi seeks $150M from investors, with option for $22.5M more - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week HighTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high at 14.4 USD By Investing.com - Investing.com Canada
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Inflation Data: Is Trevi Therapeutics Inc a top pick in the sectorChart Signals & Safe Entry Trade Reports - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN
Trevi Therapeutics (TRVI) asks shareholders to approve stock-plan refresh and share increase - Stock Titan
Stock Market Recap: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Trevi Therapeutics, Inc. (TRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2%Here's What Happened - MarketBeat
Trevi Therapeutics, Inc. (TRVI) stock price, news, quote and history - Yahoo Finance Singapore
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough - Yahoo Finance
Trevi Therapeutics (TRVI) Encounters Execution Uncertainty as Investors Anticipate Insights from May 7 Investor Day - Bitget
TRVI Technical Analysis & Stock Price Forecast - Intellectia AI
TRVI Forecast, Price Target & Analyst Ratings | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics to Participate in Upcoming Events - Sahm
Trevi brings chronic cough specialists to New York investor day - Stock Titan
These analysts revise their forecasts on Trevi Therapeutics following Q4 earnings - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4%What's Next? - MarketBeat
Aug Wrap: Will Trevi Therapeutics Inc outperform tech stocks2026 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn
TRVI SEC FilingsTrevi Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trevi Therapeutics edges higher amid takeover speculation - MSN
Research Analysts Issue Forecasts for TRVI FY2026 Earnings - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus
Trading Action: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Sahm
TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):